Acceso usuarios
* Ado-trastuzumab emtansine (Kadcyla) is a new drug labeled for the treatment of metastatic HER2-positive breast cancer after other therapy has been unsuccessful.
* The drug can cause hepatotoxicity, cardiac toxicity (including fatal), death of an embryo or fetus, and birth defects.
